FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children Provided by GlobeNewswire Mar 10, 2025 1:09pm ...

The MarketWatch News Department was not involved in the creation of this content. New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug ...

Myasthenia gravis is a life-long (chronic) autoimmune condition, which means that the body’s immune system attacks its own healthy cells. Most people with generalized myasthenia gravis (gMG) have ...

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...

It's important to tailor the treatment strategy to where a patient is in their life, says Richard J. Nowak, MD, MS, Director of the Yale Myasthenia Gravis Clinic. But which factors should you consider ...

The myasthenia gravis treatment landscape is expanding with new therapies and mechanisms, enhancing management options. Treatment decisions are complex due to patient heterogeneity and idiosyncratic ...

Please provide your email address to receive an email when new articles are posted on . Nipocalimab led to significant improvements in disease-specific metrics from baseline among patients with ...

CINCINNATI, June 19-- University of Cincinnati's Academic Health Center issued the following news release: Myasthenia gravis is a chronic autoimmune neuromuscular disease whose name, translated from ...

A study based on the EXPLORE-MG registry reveals that African-American and Hispanic patients tend to develop myasthenia gravis (MG) at younger ages and experience more-severe symptoms, including ...

New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the ...